Sugi Predict

Sugi Predict / Compounds / SCHEMBL7688917

SCHEMBL7688917

SCHEMBL7688917

N[C@@H](Cc1c(Cl)[nH]c2ccccc12)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.54
▸ MAPT P10636 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ MPO P05164 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ EGFR P00533 4/20 0.49
▸ SRC P12931 2/20 0.49
▸ SCN9A Q15858 1/20 0.49
▸ ALPI P09923 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ XIAP P98170 1/20 0.47
▸ SLC7A5 Q01650 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8653746 1.00 KDM4E (0.54) KDM4EMAPTMEN1LMNAMPO
SCHEMBL31599467 1.00 KDM4E (0.54) KDM4EMAPTMEN1LMNAMPO
SCHEMBL5281305 1.00 KDM4E (0.54) KDM4EMAPTMEN1LMNAMPO
SCHEMBL497627 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL2263891 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL471925 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL7694812 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL6295317 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL29415605 0.84 KDM4E (0.55) KDM4EMAPTMEN1LMNAMPO
SCHEMBL12838301 0.83 KDM4E (0.51) KDM4EMAPTMEN1LMNAMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2024-07-25 — — US claimed
US-20230174596-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2023-06-08 — — US claimed
WO-2021055696-A1 METHODS FOR PRODUCING D-TRYPTOPHAN AND SUBSTITUTED D-TRYPTOPHANS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-25 — — WO claimed
US-20200325187-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH, INC. (US) 2020-10-15 — — US claimed
US-20200231636-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2020-07-23 — — US claimed
US-20180291069-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2018-10-11 — — US claimed
EP-3350215-A1 CYSTINE KNOT SCAFFOLD PLATFORM H. Hoffnabb-La Roche Ag (CH) 2018-07-25 — — EP claimed
CN-108026162-A Cystine knot scaffold platform 豪夫迈·罗氏有限公司 2018-05-11 — — CN claimed
US-20170129927-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2017-05-11 — — US claimed
WO-2017049009-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH, INC. (US) 2017-03-23 — — WO claimed
US-20260071243-A1 BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS UNIV TEXAS (US) 2026-03-12 — — US disclosed
EP-3350215-B1 CYSTINE KNOT SCAFFOLD PLATFORM HOFFMANN LA ROCHE (CH) 2025-12-03 — — EP disclosed
US-20250361273-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC 2025-11-27 — — US disclosed
WO-2025245483-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) 2025-11-27 — — WO disclosed
US-20250276998-A1 NOVEL DAROBACTIN DERIVATIVES HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2025-09-04 — — US disclosed
US-6338957-B2 CULTURING MICROORGANISM WITH MIXTURE COMPRISING HALOINDOLE, PYRUVIC ACID AND AMMONIA SOURCES, RECOVERING FOR USE AS INTERMEDIATE IN PHARMACEUTICAL PRODUCTS AJINOMOTO CO., INC. (JP) 2002-01-15 — — US disclosed
US-20010029037-A1 Method for producing halo-L-tryptophan AJINOMOTO CO., INC. (JP) 2001-10-11 — — US disclosed
EP-1132480-A1 Method for producing halo-L-tryptophan Ajinomoto Co., Inc. (JP) 2001-09-12 — — EP disclosed
EP-0707490-A1 NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS UNIVERSITY OF CINCINNATI (US) 1996-04-24 — — EP disclosed
WO-1995000161-A1 NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS UNIVERSITY OF CINCINNATI (US) 1995-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361273-A1 METHODS AND COMPOSITIONS MC4R, GPR119, MC2R KDM4E 2986/4885MAPT 3206/4885MEN1 2306/4885
US-20260071243-A1 BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS TPH1, TPH2, SLC6A4 KDM4E 3485/4885MAPT 1647/4885MEN1 3917/4885
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM LRP6, LDLR, KDR KDM4E 3727/4885MAPT 1783/4885MEN1 4072/4885
US-20250276998-A1 NOVEL DAROBACTIN DERIVATIVES HAMP, SLC40A1, DHPS KDM4E 4361/4885MAPT 3403/4885MEN1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.